- Home
- BAH vs ABVX Comparison
BAH vs ABVX Comparison
Compare BAH & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BAH | ABVX |
|---|---|---|
| Founded | 1914 | 2013 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Professional Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7B | 9.6B |
| IPO Year | 2010 | N/A |
Fundamental Metrics
Financial Performance| Metric | BAH | ABVX |
|---|---|---|
| Price | $92.38 | $121.75 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 12 |
| Target Price | $109.50 | ★ $112.83 |
| AVG Volume (30 Days) | ★ 2.2M | 1.7M |
| Earning Date | 01-30-2026 | 08-11-2025 |
| Dividend Yield | ★ 2.37% | N/A |
| EPS Growth | ★ 3.12 | N/A |
| EPS | ★ 6.54 | N/A |
| Revenue | ★ $11,706,000,000.00 | $7,073,400.00 |
| Revenue This Year | N/A | $6.80 |
| Revenue Next Year | $2.57 | N/A |
| P/E Ratio | $14.19 | ★ N/A |
| Revenue Growth | ★ 2.42 | N/A |
| 52 Week Low | $79.23 | $4.77 |
| 52 Week High | $146.95 | $138.49 |
Technical Indicators
Market Signals| Indicator | BAH | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 61.45 | 55.51 |
| Support Level | $89.97 | $107.06 |
| Resistance Level | $95.34 | $138.49 |
| Average True Range (ATR) | 2.22 | 7.25 |
| MACD | 1.48 | -0.19 |
| Stochastic Oscillator | 79.41 | 45.63 |
Price Performance
Historical ComparisonAbout BAH Booz Allen Hamilton Holding Corporation
Booz Allen Hamilton Holding Corp provides technology solutions in areas such as artificial intelligence, cybersecurity, and related fields. The company serves U.S. federal government agencies, commercial clients, and select international customers. It also provides technologies to evolve defense missions and delivers solutions to warfighters in the digital battlespace.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.